Literature DB >> 31378553

Examination of heterogeneity in treatment response to antipsychotic medications.

Natalie Bareis1, T Scott Stroup2.   

Abstract

Entities:  

Year:  2019        PMID： 31378553      PMCID： PMC6727640          DOI： 10.1016/j.schres.2019.07.033

Source DB:  PubMed          Journal:  Schizophr Res        ISSN： 0920-9964            Impact factor:   4.939


× No keyword cloud information.
  12 in total

1.  Effectiveness of switching antipsychotic medications.

Authors:  Susan M Essock; Nancy H Covell; Sonia M Davis; T Scott Stroup; Robert A Rosenheck; Jeffrey A Lieberman
Journal:  Am J Psychiatry       Date:  2006-12       Impact factor: 18.112

2.  SCID-PANSS: two-tier diagnostic system for psychotic disorders.

Authors:  S R Kay; L A Opler; R L Spitzer; J B Williams; A Fiszbein; A Gorelick
Journal:  Compr Psychiatry       Date:  1991 Jul-Aug       Impact factor: 3.735

3.  Survival analysis I: the Kaplan-Meier method.

Authors:  Vianda S Stel; Friedo W Dekker; Giovanni Tripepi; Carmine Zoccali; Kitty J Jager
Journal:  Nephron Clin Pract       Date:  2011-06-15

4.  Comparison of outcomes for African Americans, Hispanics, and Non-Hispanic Whites in the CATIE study.

Authors:  Jodi Gonzalez Arnold; Alexander L Miller; José M Cañive; Robert A Rosenheck; Marvin S Swartz; Jim Mintz
Journal:  Psychiatr Serv       Date:  2013-06       Impact factor: 3.084

5.  Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial.

Authors:  Joseph P McEvoy; Matthew Byerly; Robert M Hamer; Rosalie Dominik; Marvin S Swartz; Robert A Rosenheck; Neepa Ray; J Steven Lamberti; Peter F Buckley; Tania M Wilkins; T Scott Stroup
Journal:  JAMA       Date:  2014-05-21       Impact factor: 56.272

6.  Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

Authors:  Joseph P McEvoy; Jonathan M Meyer; Donald C Goff; Henry A Nasrallah; Sonia M Davis; Lisa Sullivan; Herbert Y Meltzer; John Hsiao; T Scott Stroup; Jeffrey A Lieberman
Journal:  Schizophr Res       Date:  2005-08-30       Impact factor: 4.939

7.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Authors:  Jeffrey A Lieberman; T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Richard S E Keefe; Sonia M Davis; Clarence E Davis; Barry D Lebowitz; Joanne Severe; John K Hsiao
Journal:  N Engl J Med       Date:  2005-09-19       Impact factor: 91.245

8.  Diagnosis of alcohol use disorders in schizophrenia.

Authors:  R E Drake; F C Osher; D L Noordsy; S C Hurlbut; G B Teague; M S Beaudett
Journal:  Schizophr Bull       Date:  1990       Impact factor: 9.306

9.  The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder.

Authors:  Matthew J Byerly; Paul A Nakonezny; A John Rush
Journal:  Schizophr Res       Date:  2008-02-05       Impact factor: 4.939

10.  The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.

Authors:  T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Matthew J Byerly; Ira D Glick; Jose M Canive; Mark F McGee; George M Simpson; Michael C Stevens; Jeffrey A Lieberman
Journal:  Schizophr Bull       Date:  2003       Impact factor: 9.306
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.